The 2026 ACC/AHA Dyslipidemia Guideline offers evidence-based recommendations for managing dyslipidemias based on a systematic review.
2
The 2025 ESC Dyslipidemia Guideline Update revises treatment recommendations using recent evidence, focusing on combination therapies and updated risk modifiers.
3
The 2022 AHA/ACC/HFSA Heart Failure Guideline provides patient-centered guidance for heart failure management based on comprehensive clinical evidence.
4
The FOURIER Trial demonstrated that evolocumab significantly lowers LDL cholesterol and reduces major cardiovascular event risks in statin users.
5
The PREVENT risk equations estimate long-term cardiovascular disease risk using patient-specific factors for adults without established cardiovascular disease.
